MCID: CRV040
MIFTS: 50

Cervix Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervix Carcinoma

MalaCards integrated aliases for Cervix Carcinoma:

Name: Cervix Carcinoma 12 15 70
Cancer of Cervix 12 29 6
Carcinoma of the Cervix Uteri 12
Carcinoma Cervix Uteri 12
Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2893
NCIt 50 C9039
SNOMED-CT 67 285432005
ICD10 32 C53 C53.9
UMLS 70 C0302592

Summaries for Cervix Carcinoma

Disease Ontology : 12 A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Cervix Carcinoma, also known as cancer of cervix, is related to suppressor of tumorigenicity 3 and cervical cancer, and has symptoms including pelvic pain An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are VEGF Signaling and Shigellosis. The drugs Metronidazole and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix uteri, cervical area and cervix, and related phenotype is neoplasm.

Wikipedia : 73 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 32.5 TP53 FHIT
2 cervical cancer 32.3 TP53 STAT3 MIR200A HOXA11-AS FHIT FGFR3
3 cervical squamous cell carcinoma 31.7 TP53 STAT3 MIR200A
4 squamous cell carcinoma 30.4 TP53 STAT3 RHOA FHIT FGFR3
5 peripheral nervous system disease 30.4 TP53 STAT3 MIR362 MIR199A1 H2AC18
6 lymphoma, non-hodgkin, familial 30.3 TP53 STAT3 RHOA MIR199A1 H2AC18 CDKN3
7 lung cancer 29.8 TP53 STAT3 RHOA MIR200A MIR199A1 MIR193B
8 high-grade neuroendocrine carcinoma of the cervix uteri 11.5
9 adenoid basal carcinoma of the cervix uteri 11.4
10 cervical clear cell adenocarcinoma 11.4
11 cervical endometrioid adenocarcinoma 11.4
12 glassy cell carcinoma of the cervix uteri 11.4
13 papillary carcinoma of the cervix uteri 11.4
14 rare cancer of cervix uteri 11.1
15 malignant mixed epithelial and mesenchymal tumor of cervix uteri 11.1
16 primitive neuroectodermal tumor of the cervix uteri 11.1
17 cervical adenosquamous carcinoma 11.1
18 cervical adenocarcinoma 11.0
19 exocervical carcinoma 11.0
20 cervical adenoid cystic carcinoma 11.0
21 cervical adenoid basal carcinoma 11.0
22 cervical large cell neuroendocrine carcinoma 11.0
23 endocervical carcinoma 11.0
24 actinic cheilitis 10.5 TP53 FGFR3
25 human papillomavirus infectious disease 10.5 TP53 FHIT
26 uterine sarcoma 10.5 ABCC1 ABCB1
27 cheilitis 10.5 TP53 STAT3 FGFR3
28 colonic benign neoplasm 10.5 TP53 STAT3 H2AC18
29 temporal lobe neoplasm 10.5 ABCC1 ABCB1
30 respiratory system benign neoplasm 10.5 TP53 MIR362 H2AC18
31 esophagus adenocarcinoma 10.5 TP53 MIR362 MIR199A1
32 peripheral t-cell lymphoma 10.5 TP53 STAT3 RHOA FGFR3
33 mature t-cell and nk-cell lymphoma 10.5 TP53 STAT3 MIR199A1 H2AC18
34 intestinal benign neoplasm 10.5 TP53 STAT3 MIR199A1 H2AC18
35 gastrointestinal system benign neoplasm 10.5 TP53 STAT3 MIR199A1 H2AC18
36 pleural cancer 10.5 TP53 MIR200A H2AC18
37 sexual disorder 10.5 RHOA MIR141 H2AC18
38 lymphangioma 10.5 TP53 STAT3 H2AC18
39 skeletal muscle cancer 10.5 TP53 MIR199A1 H2AC18
40 muscle cancer 10.5 TP53 MIR199A1 H2AC18
41 leukocyte disease 10.5 TP53 STAT3 MIR199A1 H2AC18
42 retinal cancer 10.5 TP53 MIR199A1 H2AC18 CDKN3
43 ovarian serous carcinoma 10.5 TP53 MIR200A MIR199A1 MIR141
44 testicular disease 10.5 TP53 MIR199A1 H2AC18
45 cholangiocarcinoma 10.5 TP53 STAT3 MIR141 FHIT
46 ocular cancer 10.5 TP53 MIR199A1 H2AC18 FHIT
47 pleural disease 10.5 TP53 MIR199A1 H2AC18
48 integumentary system disease 10.5 TP53 STAT3 MIR199A1 H2AC18
49 biliary tract disease 10.5 TP53 STAT3 MIR199A1 H2AC18
50 tonsil cancer 10.5 TP53 MIR199A1 MIR193B H2AC18

Graphical network of the top 20 diseases related to Cervix Carcinoma:



Diseases related to Cervix Carcinoma

Symptoms & Phenotypes for Cervix Carcinoma

UMLS symptoms related to Cervix Carcinoma:


pelvic pain

MGI Mouse Phenotypes related to Cervix Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 BECN1 FGFR3 FHIT FOXM1 FOXO3 STAT3

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3 Anti-Bacterial Agents Phase 2, Phase 3
4 Antiparasitic Agents Phase 2, Phase 3
5 Antiprotozoal Agents Phase 2, Phase 3
6
Gemcitabine Approved Phase 2 95058-81-4 60750
7
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
8 Mitomycins Phase 2
9 Antiemetics Phase 2
10 Immunosuppressive Agents Phase 2
11 Immunologic Factors Phase 2
12 Antiviral Agents Phase 2
13 Antimetabolites Phase 2
14 Immunoglobulins Phase 1, Phase 2
15 Antibodies Phase 1, Phase 2
16 Antineoplastic Agents, Immunological Phase 1, Phase 2
17 Antibodies, Monoclonal Phase 1, Phase 2
18
Proflavine Approved 92-62-6 7099
19 Fluorodeoxyglucose F18
20 Anti-Infective Agents
21 Pharmaceutical Solutions
22 Anti-Infective Agents, Local
23 Vaccines

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3
2 Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial Completed NCT02765919 Phase 3
3 High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Completed NCT00193830 Phase 3
4 Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA Completed NCT00191100 Phase 3 Gemcitabine;Cisplatin
5 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
6 A Prospective Randomized Trial of Neoadjuvant Chemotherapy and Surgery Versus Concurrent Chemoradiation Therapy in Patients With Stage IB2-IIB Squamous Carcinoma of the Uterine Cervix Active, not recruiting NCT00193739 Phase 3 NACT;Inj.Cisplatin
7 Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial) Unknown status NCT02879214 Phase 2
8 Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression Completed NCT02309658 Phase 2 gemcitabine;cisplatin
9 A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
10 A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy. Not yet recruiting NCT04652076 Phase 1, Phase 2 NP137;Pembrolizumab;Paclitaxel;Carboplatin
11 A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors Withdrawn NCT02312804 Phase 1 BGJ398;Carboplatin;Paclitaxel
12 The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus Unknown status NCT00154479
13 Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation Unknown status NCT01049100
14 A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix Completed NCT00193804
15 Concomitant Chemo-radiation in Advanced Stage Carcinoma Cervix: A Phase III Randomized Trial Completed NCT00193791
16 Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cervical Cancer Completed NCT00193752
17 A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy Completed NCT01991808
18 Vaginal Length, Elasticity, Lubrication And Sexual Function In Women With Stage IB2 Cervix Carcinoma Completed NCT00053261
19 Predicting Outcome in Cervix Carcinoma: a Prospective Study Completed NCT01825005
20 Standard Follow-up Program Cervix Cancer (SFP CERVIX) Recruiting NCT02733289
21 Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study Active, not recruiting NCT01759355
22 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Proflavine
23 A Nonrandomized, Non-double Blinded Prospective Cohort Study to Evaluate the Preventive Efficacy of Quadrivalent HPV6/11/16/18 Vaccine for the Persistent Infection of HPV16 Genotype or HPV18 Genotype in Japanese Women Aged 27-45 Years. Not yet recruiting NCT04022148
24 Study Evaluating Predictive Value of Local Control at 19.8 (MRI and TEP Scan) for Patient With Stade I to IIIB Cervix Carcinoma Treated by Radiotherapy Terminated NCT01641484

Search NIH Clinical Center for Cervix Carcinoma

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

# Genetic test Affiliating Genes
1 Cancer of Cervix 29 FGFR3

Anatomical Context for Cervix Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Carcinoma:

19
Cervix Uteri, Cervical Area

MalaCards organs/tissues related to Cervix Carcinoma:

40
Cervix, Lymph Node, Breast, Bone, Uterus, Skin, Brain

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show top 50) (show all 1452)
# Title Authors PMID Year
1
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
2
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 6
10471491 1999
3
Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. 6
8589699 1995
4
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. 6
1349102 1992
5
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 6
1849234 1991
6
Luminescent cyclometalated platinum(II) complexes with acyclic diaminocarbene ligands: structural, photophysical and biological properties. 61
33729268 2021
7
Mitochondria specific highly cytoselective iridium(iii)-Cp* dipyridophenazine (dppz) complexes as cancer cell imaging agents. 61
33507192 2021
8
Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4-Methoxybenzyl Derivatives Bearing Imidazo[2,1-b][1,3,4]thiadiazole. 61
33274824 2021
9
Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy. 61
33673002 2021
10
PEPCK-M recoups tumor cell anabolic potential in a PKC-ζ-dependent manner. 61
33413684 2021
11
PI3KCA Mutations in Uterine Cervix Carcinoma. 61
33435133 2021
12
Modification of multiwalled carbon nanotubes with a ruthenium drug candidate-indazolium[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 ). 61
33174575 2020
13
Biological Properties of New Chiral 2-Methyl-5,6,7,8-tetrahydroquinolin-8-amine-based Compounds. 61
33260896 2020
14
Two new triterpenoid fatty acid esters from Schefflera barteri Harms (Araliaceae)§. 61
33203260 2020
15
Further Approaches in the Design of Antitumor Agents with Response to Cell Resistance: Looking toward Aza Crown Ether-dtc Complexes. 61
33000942 2020
16
A novel peptide-based electrochemical biosensor for the determination of a metastasis-linked protease in pancreatic cancer cells. 61
31989193 2020
17
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. 61
32775490 2020
18
Development of oxathiino[6,5-b]pyridine 2,2-dioxide derivatives as selective inhibitors of tumor-related carbonic anhydrases IX and XII. 61
32460112 2020
19
Immunology of HPV-mediated cervical cancer: current understanding. 61
32853049 2020
20
Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. 61
31407252 2020
21
First report of compounds from an Ancistrocarpus species: Triterpenoids from A. densispinosus Oliv. (Malvaceae). 61
32598239 2020
22
A new class of dimeric product isolated from the fungus Chaetomium globosum: evaluation of chemical structure and biological activity. 61
32024969 2020
23
Antiviral, Antibacterial, Antifungal, and Cytotoxic Silver(I) BioMOF Assembled from 1,3,5-Triaza-7-Phoshaadamantane and Pyromellitic Acid. 61
32369972 2020
24
Human papilloma virus-associated metachronous squamous cell carcinoma of the larynx and uterine cervix: Case report and review of the literature. 61
32300633 2020
25
Synthesis of novel feruloyl dipeptides with proapoptotic potential against different cancer cell lines. 61
32120076 2020
26
New cyclopeptide alkaloids from the whole plant of Justicia procumbens L. 61
32347116 2020
27
Terretonin O: a new meroterpenoid from Aspergillus terreus. 61
30602325 2020
28
Isoshamixanthone: a new pyrano xanthone from endophytic Aspergillus sp. ASCLA and absolute configuration of epiisoshamixanthone. 61
30663363 2020
29
Meleagrin from marine fungus Emericella dentata Nq45: crystal structure and diverse biological activity studies. 61
32189530 2020
30
Evaluation of the cytotoxic and genotoxic effects of mycotoxin fusaric acid. 61
30204001 2020
31
Cervix neuroendocrine carcinoma presenting with severe hypokalemia and Cushing's syndrome. 61
31970585 2020
32
Synthesis, Structural, and Cytotoxic Properties of New Water-Soluble Copper(II) Complexes based on 2,9-Dimethyl-1,10-Phenanthroline and Their One Derivative Containing 1,3,5-Triaza-7-Phosphaadamantane-7-Oxide. 61
32046362 2020
33
Intracardiac metastasis from unknown uterine cervical cancer with severe thrombocytopenia. 61
31765009 2020
34
Structurally diverse metabolites from the rare actinobacterium Saccharothrix xinjiangensis. 61
31451754 2020
35
Design, Synthesis, and Biological Evaluation of Novel C5-Modified Pyrimidine Ribofuranonucleosides as Potential Antitumor or/and Antiviral Agents. 61
30799795 2020
36
Impact of diabetes on gastrointestinal and urinary toxicity after radiotherapy for gynecologic malignancy. 61
32231858 2019
37
A case report of carcinoma of uterine cervix throwing heterochronous metastasis to the skin, spleen, and pancreas: the role of multimodality treatment approach. 61
32372163 2019
38
Evaluation of Volumetric Doses of Organs at Risk in Carcinoma Cervix Patients with HDR Intracavitary Brachytherapy and Comparison of CT-based and Conventional Plans. 61
32039090 2019
39
Synthesis and cytotoxic activities of novel copper and silver complexes of 1,3-diaryltriazene-substituted sulfonamides. 61
30362387 2019
40
On the potential use of dynamic contrast-enhanced (DCE) MRI parameters as radiomic features of cervical cancer. 61
31523829 2019
41
Pentafluorophenyl Platinum(II) Complexes of PTA and its N-Allyl and N-Benzyl Derivatives: Synthesis, Characterization and Biological Activity. 61
31779206 2019
42
Graphene oxide size and structure pro-oxidant and antioxidant activity and photoinduced cytotoxicity relation on three cancer cell lines. 61
31648133 2019
43
Formulation of normal tissue irradiation volumes in Co-60 and Ir-192 HDR ICBT of Ca cervix using Total Reference Air Kerma (TRAK). 61
31660050 2019
44
Overcoming radioresistance in WiDr cells with heavy ion irradiation and radiosensitization by 2-deoxyglucose with photon irradiation. 61
31517070 2019
45
Nodal metastasis of cervix carcinoma- As a probable cause of bone erosion. 61
31898657 2019
46
Corrigendum to "Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity" [Biomed. Pharmacother. 105 (2018) 758-765]. 61
31227337 2019
47
Coumamarin: a first coumarinyl calcium complex isolated from nature. 61
31289369 2019
48
Correlation between cervical carcinogenesis and tobacco use by sexual partners. 61
31802062 2019
49
The efficacy of modified Swede Colposcopic Index in prediction of high-grade lesion and cancer of cervix. 61
31328460 2019
50
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. 61
30411218 2019

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

6 (show all 13)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.747G>T SNV Pathogenic 12352 rs28934571 GRCh37: 17:7577534-7577534
GRCh38: 17:7674216-7674216
2 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic 16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
3 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic 16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
4 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic 65855 rs121913105 GRCh37: 4:1807890-1807890
GRCh38: 4:1806163-1806163
5 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic 16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
6 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic 16340 rs4647924 GRCh37: 4:1803571-1803571
GRCh38: 4:1801844-1801844
7 FGFR3 NM_000142.5(FGFR3):c.1138G>A SNV Pathogenic 16327 rs28931614 GRCh37: 4:1806119-1806119
GRCh38: 4:1804392-1804392
8 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic 16338 rs28933068 GRCh37: 4:1807371-1807371
GRCh38: 4:1805644-1805644
9 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic 16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
10 FGFR3 NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp) SNV Uncertain significance 546226 rs369232922 GRCh37: 4:1801071-1801071
GRCh38: 4:1799344-1799344
11 FGFR3 NM_000142.5(FGFR3):c.1993G>T (p.Ala665Ser) SNV Uncertain significance 465350 rs764892330 GRCh37: 4:1808017-1808017
GRCh38: 4:1806290-1806290
12 FGFR3 NM_000142.5(FGFR3):c.2153A>G (p.Asn718Ser) SNV Uncertain significance 521225 rs139773438 GRCh37: 4:1808395-1808395
GRCh38: 4:1806668-1806668
13 FGFR3 NM_000142.5(FGFR3):c.1960-16T>C SNV Uncertain significance 931624 GRCh37: 4:1807968-1807968
GRCh38: 4:1806241-1806241

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Pathways for Cervix Carcinoma

GO Terms for Cervix Carcinoma

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.89 MIR362 MIR200A MIR199A1 MIR193B MIR141
2 negative regulation of cell death GO:0060548 9.61 STAT3 RHOA BECN1
3 negative regulation of autophagy GO:0010507 9.58 STAT3 MIR199A1 BECN1
4 cellular response to glucose starvation GO:0042149 9.54 TP53 FOXO3 BECN1
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.51 TP53 FOXM1
6 export across plasma membrane GO:0140115 9.48 ABCC1 ABCB1
7 transepithelial transport GO:0070633 9.46 ABCC1 ABCB1
8 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.43 TP53 STAT3 FOXO3
9 carboxylic acid transmembrane transport GO:1905039 9.32 ABCC1 ABCB1
10 positive regulation of neuron apoptotic process GO:0043525 9.26 TP53 RHOA MIR200A FOXO3
11 lactone transport GO:0042969 9.16 ABCC1 ABCB1
12 response to drug GO:0042493 9.1 TP53 STAT3 RHOA BECN1 ABCC1 ABCB1

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.55 MIR362 MIR200A MIR199A1 MIR193B MIR141
2 protein phosphatase binding GO:0019903 9.54 TP53 STAT3 CDC27
3 efflux transmembrane transporter activity GO:0015562 9.4 ABCC1 ABCB1
4 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.32 ABCC1 ABCB1
5 carboxylic acid transmembrane transporter activity GO:0046943 9.26 ABCC1 ABCB1
6 protein kinase binding GO:0019901 9.17 TP53 STAT3 RHOA FOXO3 FOXM1 DUSP3
7 lactone transmembrane transporter activity GO:0042971 8.96 ABCC1 ABCB1

Sources for Cervix Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....